Novavax Inc. ($NVAX) Stock Forecast: Up 13.4% Today

What is Novavax Inc.?

Novavax Inc. (NVAX) is a biotechnology company focused on developing innovative vaccines for a range of infectious diseases, including COVID-19. The company has been in the spotlight for its vaccine technology and strategic partnerships in the healthcare sector.

Why is Novavax Inc. going up?

NVAX stock is up 13.4% on May 8, 2026 17:21

• Novavax's stock experienced a strong bullish movement of 13.98% following a robust Q1 earnings report and positive developments in its COVID-19 vaccine technology, driven by the following factors:
• The announcement of a licensing deal with Pfizer for its Matrix-M adjuvant technology and an expanded partnership with Sanofi boosted investor confidence in the company's future growth potential.
• The unexpected revenue beat in Q1, amounting to $139.5 million, surpassed analysts' expectations and showcased Novavax's ability to pivot towards a licensing model, reducing its reliance on direct vaccine sales.
• Participation in the BofA Securities 2026 Health Care Conference further highlighted Novavax's strategic positioning and potential for future collaborations and advancements in the healthcare industry.
• Despite a slight underperformance compared to competitors on a previous trading day, the overall positive sentiment surrounding Novavax's recent developments and financial outlook contributed to the bullish market movement.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax Stock Jumps As Pfizer Deal And Q1 Beat Energize Traders

Novavax Inc. (NASDAQ: NVAX) stock soared by 13.98% following a strong Q1 2026 earnings report and positive developments with its COVID-19 vaccine technology. The company reported revenue significantly above consensus and a narrower loss per share, driven by a licensing deal with Pfizer for its Matrix-M adjuvant technology and an expanded partnership with Sanofi. This shift in narrative from a struggling COVID-19 vaccine company to a platform-and-partners model has energized traders, despite ongoing negative equity and cash burn concerns.

https://www.timothysykes.com/news/novavax-inc-nvax-news-2026_05_08/

[144] NOVAVAX INC SEC Filing

NOVAVAX INC (NVAX) has filed a Form 144 Notice of Proposed Sale of Securities with the SEC. The filing indicates a proposed sale of 30,000 common shares acquired through stock plan activity, with an aggregate market value of $296,083, to be sold on NASDAQ via Merrill Lynch. This filing is classified as neutral in both impact and sentiment.

https://www.stocktitan.net/sec-filings/NVAX/144-novavax-inc-sec-filing-5a962d1d0d8b.html

Novavax to Participate in BofA Securities 2026 Health Care Conference

Novavax, Inc. announced its participation in the BofA Securities 2026 Health Care Conference. A fireside chat featuring Novavax is scheduled for Wednesday, May 13, 2026, at 3:00 – 3:30 p.m. Pacific Time in Las Vegas, NV, and will be webcast live. The company will also hold investor meetings on the same day.

https://www.prnewswire.com/news-releases/novavax-to-participate-in-bofa-securities-2026-health-care-conference-302765891.html

Novavax Inc. stock underperforms Thursday when compared to competitors

Novavax Inc. (NVAX) shares fell 1.39% on Thursday, closing at $9.23, amid a general market decline with the NASDAQ Composite Index and Dow Jones Industrial Average also experiencing losses. This drop ended a two-day winning streak for the company's stock. The stock's performance indicates it underperformed compared to its competitors during this trading session.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-thursday-when-compared-to-competitors-896169fc-e08324bf39b3

Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax's stock jumped after reporting first-quarter revenue of $139.5 million, significantly beating analysts' estimates, primarily due to licensing and supply payments for its Matrix-M adjuvant technology. This financial pivot, driven by a key deal with Pfizer and an existing partnership with Sanofi, signals a strategic shift from direct COVID-19 vaccine sales to a licensing model. The company aims for greater insulation from market volatility and is also developing a C. difficile vaccine candidate, targeting profitability around 2028.

https://ts2.tech/en/novavax-inc-stock-jumps-why-pfizers-matrix-m-deal-drove-a-surprise-q1-revenue-beat/

Trending Today

Aave ($AAVE) Crypto Forecast: Up 5.2% Today

ZCash ($ZEC) Crypto Forecast: Up 6.0% Today

Power Integrations Inc. ($POWI) Stock Forecast: Down 7.2% Today

CDW Corporation ($CDW) Stock Forecast: Down 5.2% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 8.0% Today

Microchip Technology Incorporated ($MCHP) Stock Forecast: Down 5.1% Today

Sunrun Inc. ($RUN) Stock Forecast: Up 5.3% Today

BorgWarner Inc. ($BWA) Stock Forecast: Up 5.1% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Up 7.6% Today

The Trade Desk Inc ($TTD) Stock Forecast: Down 5.1% Today

Novavax Inc. Price History

07.04.2026 - NVAX Stock was down 7.6%

• Despite a decline in revenue and a shift to a net loss in Q1 2026, Novavax's stock surged by 17.4%. Investors seemed to focus on the company's new partnership approach and future potential earnings rather than its financial results.
• Novavax initially saw its stock rise due to strong first-quarter financial results, which surpassed sales expectations and emphasized strategic collaborations. Nevertheless, the market sentiment shifted, resulting in the recent bearish trend.
• Novavax's stock had been performing well in recent trading sessions, outpacing competitors and benefiting from a favorable market environment. Profit-taking activities today likely triggered the observed bearish movement.

07.04.2026 - NVAX Stock was up 4.1%

• Despite facing a significant revenue drop and transitioning to a net loss in Q1 2026, Novavax saw a 17.4% increase in its stock value, indicating investor confidence in its shift to an asset-light, partnership-focused business strategy.
• The company's Q1 financial performance surpassed expectations, surpassing sales forecasts and demonstrating a strengthened financial position through new credit facilities and key partnerships, driving the positive movement in Novavax's stock.
• Novavax reiteration of its 2026 sales outlook, combined with optimistic technical analysis signaling a decrease in downward pressure, further bolstered investor confidence, contributing to the stock's robust performance.
• Novavax's strong stock performance was also evidenced by its outperformance relative to competitors on a flourishing trading day, during which both the NASDAQ Composite and Dow Jones Industrial Average experienced significant gains.

02.03.2026 - NVAX Stock was down 5.0%

• An investment firm, Shah Capital Management, significantly increased its stake in Novavax during Q4, showing confidence in the company's future despite the recent stock decline. This move could indicate a long-term positive outlook on NVAX.
• The appointment of Dr. Robert Walker as the new Executive Vice President and Head of Research & Development brings in a seasoned professional with extensive experience in drug and vaccine development. This change in leadership might signal a strategic shift or renewed focus on research and development efforts.
• The underperformance of Novavax's stock compared to its competitors, despite positive quarterly earnings and revenue growth, suggests that market sentiment or external factors may be influencing investor behavior. This disparity could be a result of broader industry trends or specific company challenges that need addressing.
• The departure of the previous R&D chief after a short tenure and the subsequent internal promotion highlight potential internal restructuring within Novavax. This organizational change could be impacting investor confidence and contributing to the stock's bearish movement.

23.03.2026 - NVAX Stock was down 5.5%

• Novavax's stock has been experiencing volatility, with recent bearish movements following two consecutive days of losses.
• The underperformance of Novavax's stock can be attributed to concerns raised by activist investor Himanshu Shah regarding governance, operational shortcomings, and disappointing sales of its Covid vaccine Nuvaxovid.
• Additionally, the call by PETA for Novavax to investigate experiments using monkeys from a controversial lab may have added negative sentiment to the stock.
• Despite these challenges, Wall Street analyst Mayank Mamtani remains optimistic about Novavax's potential, especially driven by upcoming milestones from its Sanofi partnership.

08.03.2026 - NVAX Stock was up 5.6%

• A major investor in Novavax, Shah Capital, has initiated efforts to revamp the company's board and leadership, citing concerns about previous missteps and lower-than-expected vaccine sales.
• Criticisms from this investor regarding Novavax's direction and management have prompted a shareholder movement, increasing pressure on the company to make changes.
• Shah Capital's decision to vote against board nominees and executive pay has hinted at potential management changes within Novavax, resulting in a rise in the stock's value.
• Investor enthusiasm for Shah Capital's proposals for strategic changes, cost reductions, and a possible company sale has led to a positive market response, indicating optimism for a revitalization in Novavax's performance and shareholder interests.

15.03.2026 - NVAX Stock was up 5.4%

• An increased stake by SHAH CAPITAL MANAGEMENT in Novavax Inc demonstrates confidence in the company's vaccine development potential, despite concerns about overvaluation and poor growth indicators.
• Novavax's pivot towards a diversified pipeline of vaccines, utilizing its protein-based platform and Matrix-M adjuvant technology, is viewed favorably by investors for sustainable growth and reduced reliance on single products.
• The revenue breakdown of the company emphasizes the strong performance of its "Innovative Vaccines" segment, signaling a positive outlook for its vaccine development efforts.
• Despite recent stock price underperformance compared to peers, the long-term value of Novavax and its potential for FDA approvals, successful clinical readouts, and strategic partnerships are driving investor interest and the current bullish movement in the market.

30.03.2026 - NVAX Stock was up 6.1%

• The upcoming release of Novavax's first-quarter 2026 financial results created excitement among investors.
• A director of the company showed confidence in Novavax's future by exercising Restricted Stock Units (RSUs), which positively influenced investor sentiment.
• Despite recent underperformance, Novavax's stock experienced a notable upturn today, potentially linked to growing optimism about the company's financial prospects and operational achievements.
• The stock's bullish movement may have been influenced by broader market dynamics or sector-specific developments benefitting biotech firms like Novavax.

10.03.2026 - NVAX Stock was down 5.2%

• Novavax's stock had a bearish movement despite outperforming competitors and the broader market in the past few days, indicating a shift in investor sentiment.
• The increase in price target to $18 from $16 and maintaining a Buy rating did not seem to positively impact the stock, suggesting other factors are at play.
• Criticisms regarding Novavax's strategy, calls to slash costs, and overhaul the board of directors might have contributed to the bearish movement as investors react to uncertainties surrounding the company's future direction.
• The lackluster Q4 earnings, projected revenue decline, and cash flow concerns highlighted in the analysis post-earnings could have further fueled the negative market sentiment towards Novavax, leading to the bearish movement.

06.04.2026 - NVAX Stock was up 14.4%

• Novavax (NVAX) stock exhibited robust bullish growth, surpassing industry peers and the general market.
• Despite predictions of a notable decline in year-on-year revenue, Novavax's stock price surged, potentially influenced by positive outlook or expectations regarding the upcoming earnings.
• The investment stake by Vanguard Capital Management, a significant yet passive investor, could have also played a role in the favorable market dynamics.
• Observers are eagerly anticipating Novavax's financial results for the first quarter of 2026, with the impending disclosure likely fueling the current positive momentum in the stock price.

06.04.2026 - NVAX Stock was up 19.1%

• Novavax reported first-quarter revenue of $139.5 million, surpassing estimates by a significant margin, showcasing strong financial performance.
• The company's revenue was driven by milestone payments from vaccine supply and licensing deals, offsetting declining demand for its COVID-19 vaccine.
• Novavax's strategy of licensing its vaccine technology to other pharmaceutical companies has helped insulate it from uncertainties and cut costs, contributing to its positive earnings report.
• Despite facing pressure from activist investors and missing revenue forecasts in the past, Novavax's stock outperformed competitors on the back of its strong financial results, indicating investor confidence in the company's future prospects.

08.04.2026 - NVAX Stock was up 8.8%

• NVAX's stock exhibited strong bullish movement recently.
• The filing of a Form 144 Notice of Proposed Sale of Securities introduced some initial uncertainty but was later overshadowed by positive developments.
• NVAX's participation in the BofA Securities 2026 Health Care Conference was met with investor interest and confidence in the company's future.
• A surprising Q1 revenue beat was attributed to a significant deal with Pfizer and a shift towards a licensing model, illustrating NVAX's agility and innovation in a competitive market, leading to the positive movement in its stock price.

08.04.2026 - NVAX Stock was up 13.4%

• Novavax's stock experienced a strong bullish movement of 13.98% following a robust Q1 earnings report and positive developments in its COVID-19 vaccine technology, driven by the following factors:
• The announcement of a licensing deal with Pfizer for its Matrix-M adjuvant technology and an expanded partnership with Sanofi boosted investor confidence in the company's future growth potential.
• The unexpected revenue beat in Q1, amounting to $139.5 million, surpassed analysts' expectations and showcased Novavax's ability to pivot towards a licensing model, reducing its reliance on direct vaccine sales.
• Participation in the BofA Securities 2026 Health Care Conference further highlighted Novavax's strategic positioning and potential for future collaborations and advancements in the healthcare industry.
• Despite a slight underperformance compared to competitors on a previous trading day, the overall positive sentiment surrounding Novavax's recent developments and financial outlook contributed to the bullish market movement.